title: Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
abstract: Treatment with radiolabeled somatostatin analogs is a promising tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all (111)Indium-, (90)Yttrium-, or (177)Lutetium-labeled somatostatin analogs used for peptide receptor radionuclide therapy. If kidney protective agents are used, the side-effects are few and mild, and the median duration of the therapy response is 30 and 40 months, respectively. Overall survival is several years from diagnosis. These data compare favorably with the limited number of alternative treatments. If more widespread use of PRRT can be guaranteed, such therapy may become the therapy of first choice.
authors.affiliation: Department of Nuclear Medicine, Erasmus Medical Center, 's Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. d.j.kwekkeboom@erasmusmc.nl
authors.forename: Dik J
authors.initials: DJ
authors.lastname: Kwekkeboom
authors.forename: Wouter W
authors.initials: WW
authors.lastname: de Herder
authors.forename: Eric P
authors.initials: EP
authors.lastname: Krenning
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000401:mortality / Q000532:radiotherapy; D006801:Humans; D007205:Indium Radioisotopes / Q000627:therapeutic use; D008187:Lutetium / Q000627:therapeutic use; D058990:Molecular Targeted Therapy / Q000379:methods*; D018358:Neuroendocrine Tumors / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000401:mortality / Q000532:radiotherapy; D015282:Octreotide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000401:mortality / Q000532:radiotherapy; D011868:Radioisotopes / Q000627:therapeutic use; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D017481:Receptors, Somatostatin / Q000037:antagonists & inhibitors*; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D007205:Indium Radioisotopes; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D015021:Yttrium Radioisotopes; D008187:Lutetium; D015282:Octreotide